Researchers from the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in conjunction with the Center for Advanced Molecular Diagnostics in the Pathology Department at the Brigham and Women's Hospital and the Laboratory for Molecular Medicine at the Partners Healthcare Center for Personalized Genetic Medicine, introduced prospective genotyping of advanced NSCLC for somatic alterations in BRAF, HER2, PIK3CA, and ALK in July 2009, in addition to routine mutational analysis of EGFR and KRAS, which had been ongoing since 2004. Three-hundred forty-four specimens taken from 419 patients were successfully genotyped with a median turnaround time of 31 days.
"The goals of the genomic characterization of our NSCLC patients are to help guide therapy and ultimately lead to improved outcomes for those patients with specific genomic changes," the authors say. "As the repertoire of mutations for which targeted therapy may be offered expands in lung cancer and other solid malignancies, strategies to enable rapid, accurate and comprehensive clinical genotyping will be essential to successfully integrate tumor molecular analysis into the fast pace of clinical decision making and yield its greatest potential impact on patient management."
The lead author of this work is IASLC member Dr. Stephanie Cardarella. Co-authors include IASLC members Dr. Pasi Jänne, Dr. Bruce Johnson and Dr. David Kwiatkowski.
International Association for the Study of Lung Cancer
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
International Association for the Study of Lung Ca. "Large-Scale Genomic Testing Feasible, Impacts Therapy According To Study." Medical News Today. MediLexicon, Intl., 19 Nov. 2012. Web.
24 Aug. 2016. <http://www.medicalnewstoday.com/releases/252909.php>
International Association for the Study of Lung Ca. (2012, November 19). "Large-Scale Genomic Testing Feasible, Impacts Therapy According To Study." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.